Overview

Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label Phase 1 pharmacokinetic, tolerability, and safety study of ondansetron and Hylenex given subcutaneously compared to ondansetron given intravenously, intramuscularly, and orally in normal healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Halozyme Therapeutics
Treatments:
Ondansetron
Pharmaceutical Solutions